1-7 of 7
Fernando Doñate
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Potential Mechanism for ADC-Induced Neutropenia: Role of Neutrophils in Their Own Demise

Hui Zhao, Sara Gulesserian, Maria Christina Malinao, Sathish Kumar Ganesan, James Song, Mi Sook Chang, Melissa M. Williams, Zhilan Zeng, Michael Mattie, Brian A. Mendelsohn, David R. Stover, Fernando Doñate
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (9): 1866–1876.
https://doi.org/10.1158/1535-7163.MCT-17-0133
Published: 04 September 2017
View articletitled, A Potential Mechanism for ADC-Induced Neutropenia: Role of Neutrophils in Their Own Demise
Open the PDF for A Potential Mechanism for ADC-Induced Neutropenia: Role of Neutrophils in Their Own Demise in another window
Includes: Supplementary data
Journal Articles

Inhibition of Megakaryocyte Differentiation by Antibody–Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia

Hui Zhao, Sara Gulesserian, Sathish Kumar Ganesan, Jimmy Ou, Karen Morrison, Zhilan Zeng, Veronica Robles, Josh Snyder, Lisa Do, Hector Aviña, Sher Karki, David R. Stover, Fernando Doñate
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (9): 1877–1886.
https://doi.org/10.1158/1535-7163.MCT-16-0710
Published: 04 September 2017
View articletitled, Inhibition of Megakaryocyte Differentiation by Antibody–Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia
Open the PDF for Inhibition of Megakaryocyte Differentiation by Antibody–Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia in another window
Includes: Supplementary data
Journal Articles

The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer

Michael Mattie, Arthur Raitano, Kendall Morrison, Karen Morrison, Zili An, Linnette Capo, Alla Verlinsky, Monica Leavitt, Jimmy Ou, Rossana Nadell, Hector Aviña, Claudia Guevara, Faisal Malik, Ruth Moser, Steven Duniho, Jeffrey Coleman, Ying Li, Daniel S. Pereira, Fernando Doñate, Ingrid B.J. Joseph, Pia Challita-Eid, Dennis Benjamin, David R. Stover
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (11): 2679–2687.
https://doi.org/10.1158/1535-7163.MCT-16-0225
Published: 01 November 2016
View articletitled, The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer
Open the PDF for The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Development of ASG-15ME, a Novel Antibody–Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker

Kendall Morrison, Pia M. Challita-Eid, Arthur Raitano, Zili An, Peng Yang, Joseph D. Abad, Wendy Liu, Dawn Ratay Lortie, Josh T. Snyder, Linnette Capo, Alla Verlinsky, Hector Aviña, Fernando Doñate, Ingrid B.J. Joseph, Daniel S. Pereira, Karen Morrison, David R. Stover
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (6): 1301–1310.
https://doi.org/10.1158/1535-7163.MCT-15-0570
Published: 02 June 2016
View articletitled, Development of ASG-15ME, a Novel Antibody–Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker
Open the PDF for Development of ASG-15ME, a Novel Antibody–Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker in another window
Includes: Supplementary data
Journal Articles

AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML

Daniel S. Pereira, Claudia I. Guevara, Liqing Jin, Nathan Mbong, Alla Verlinsky, Ssucheng J. Hsu, Hector Aviña, Sher Karki, Joseph D. Abad, Peng Yang, Sung-Ju Moon, Faisal Malik, Michael Y. Choi, Zili An, Kendall Morrison, Pia M. Challita-Eid, Fernando Doñate, Ingrid B.J. Joseph, Thomas J. Kipps, John E. Dick, David R. Stover
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (7): 1650–1660.
https://doi.org/10.1158/1535-7163.MCT-15-0067
Published: 06 July 2015
View articletitled, AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML
Open the PDF for AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML in another window
Includes: Supplementary data
Journal Articles

Abstract A247: Mechanism of action of the hypoxia-activated irreversible pan-HER inhibitor SN29966.

Jeff B. Smaill, Jagdish Jaiswal, Maria Abbattista, Guo-Liang Lu, Robert F. Anderson, Amir Ashoorzadeh, William A. Denny, Fernando Donate, Huai-Ling Hsu, Ho H. Lee, Andrej Maroz, Sunali Mehta, Alison Pruijn, Michelle Puryer, Sophie P. Syddall, Aaron Thompson, Wouter van Leeuwen, William R. Wilson, Stephen Jamieson, Adam V. Patterson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A247.
https://doi.org/10.1158/1535-7163.TARG-11-A247
Published: 12 November 2011
View articletitled, Abstract A247: Mechanism of action of the hypoxia-activated irreversible pan-HER inhibitor SN29966.
Journal Articles

A monoclonal antibody targeting the human urokinase plasminogen activator receptor (uPAR) combined with bevacizumab inhibits the growth of colon cancer metastases in the liver: Differential effects mediated by tumor burden.

George Van Buren, Michael Gray, Nikolaos Dallas, Ling Xia, Jose Juarez, Graham Parry, Fernando Donate, Andrew Mazar, Lee Ellis
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A65.
Published: 01 November 2007
View articletitled, A monoclonal antibody targeting the human urokinase plasminogen activator receptor (uPAR) combined with bevacizumab inhibits the growth of colon cancer metastases in the liver: Differential effects mediated by tumor burden.